Presentation of Case
An eight-year-old boy from Togo presented with a nodule of 30 mm in diameter at the left costal arch ( Figure 1 ) clinically compatible with Buruli ulcer disease (BUD) at the ''Centre Hospitalier Régional Maritime'' (CHR Maritime), Tsévié, in July 2010. His hometown, a village located close to the river ''Haho'' in the central district ''Yoto'' of the ''Région Maritime'', constitutes one of the BUD-endemic foci in Togo [1] . The patient's BCG vaccination status was positive and no other family member was diagnosed with BUD before. The lesion was laboratory confirmed by conventional IS2404 PCR from a 3-mm punch biopsy sample (Table 1) at the Department of Infectious Diseases and Tropical Medicine (DITM), Munich, and a full course of rifampicin (300 mg/d) and streptomycin (0.5 g/d) was administered for eight weeks at the peripheral health post (''Unité de Soins Périphérique'', USP). The patient was fully compliant throughout the entire period of treatment and no complications were reported. In September 2010, the lesion was completely healed under scarification ( Figure 2 ) and the patient was considered cured. Weekly follow-up was conducted by the BUD nurse of the village for three months following healing accompanied by monthly follow-up by the BUD nurse of CHR Maritime. No pathological findings were observed until June 2011. In July 2011, the boy (in the meantime nineyear-old) presented again with a secondary nodule (diameter: 30 mm) at the back of the right thigh ( Figure 3 ) at CHR Maritime one week after its emergence. The lesion was clinically compatible with BUD and clinical samples were collected and forwarded to the newly established BUD Reference Laboratory at the ''Institut National d'Hygiène'' (INH), Lomé, as well as DITM (Table 1) . Microscopy of a ZiehlNeelsen stained FNA smear was (scanty) positive and the presence of Mycobacterium ulcerans DNA was confirmed by IS2404 real-time qPCR at DITM while conventional IS2404 PCR remained negative for all samples tested. The secondary lesion ulcerated three weeks after emergence and further samples were collected from the ulcer (diameter: 25630 mm) and forwarded to DITM for analysis. Whereas IS2404 qPCR reconfirmed the presence of M. ulcerans DNA, viability testing of M. ulcerans by analysis of mycobacterial ribosomal 16S RNA through a newly established 16S rRNA RT qPCR (specificity: 100%, positivity rate for pre-treatment swab samples: 83.3% [95%-CI: 66.1%-100%], limit of detection: six copies of the target sequence) (unpublished data) and culture were negative (Table 1) . Under stringent clinical observation, conventional wound care by daily cleaning with normal saline, disinfection with povidone-iodine, and sterile dressing of the ulcerated lesion was performed at the USP for two weeks. The lesion healed completely ( Figure 4 ) five weeks after onset of disease. The patient's parents gave written informed consent for publication.
Case Discussion
BUD caused by infection with M. ulcerans may lead to extensive destruction of the skin, soft tissue, and bone with severe fibrous scarring and formation of contractures if left untreated. Pathogenesis of BUD is mediated by the cytotoxic and immunosuppressive exotoxin mycolactone [2] . During the last decade, significant advances in the treatment of BUD have been made and the introduction of standardized antimycobacterial chemotherapy with rifampicin and streptomycin resulted in recurrence rates below 2% [3] .
While recurrences after surgical excision alone presumably are attributable to the persistence of mycobacteria in macroscopically healthy tissue bordering surgical excision [4] , little is known about the pathogenesis and immunological mechanisms of secondary BUD lesions evolving after completion of standardized antimycobacterial treatment [5] .
Development of new skin lesions during antimycobacterial treatment are currently assumed to be caused by immune-mediated, paradoxical reactions (i.e., deteriorating responses to treatment of an infection after initial improvement) which are likely to be triggered by mycobacterial antigens and immune-stimulators released from killed mycobacteria [6, 7] .
Ruf et al. recently reported two BUD patients from Benin who developed a series of secondary BUD lesions after completion of chemotherapy [5] . These lesions may partly represent secondary infection foci that were already present during treatment and appeared as a consequence of delayed paradoxical reactions. However, in particular, lesions occurring more than one year after completion of treatment may have been associated with new M. ulcerans infection or mycobacteria surviving antimycobacterial treatment and may have been resolved by immune responses triggered by successful treatment of primary lesions.
In accordance with the other cases published so far, in the present case a secondary M. ulcerans lesion was laboratory confirmed by microscopic detection of acid fast bacilli and IS2404 real-time qPCR, whereas cultures remained negative. Furthermore, analysis of mycobacterial ribosomal 16S RNA did not provide evidence for the presence of viable bacilli.
As shown by Ruf et al. histopathological analysis of surgically excised late-onset secondary lesions revealed characteristical features of BUD as well as massive leukocyte infiltration of necrotic areas characteristic for successfully treated lesions. As there was no surgical intervention for the secondary lesion of the Togolese patient, clinical samples for histopathological analysis were not available.
Pathogenesis of the secondary BUD lesion in the present case might either be attributable to a second unrecognized focus of killed M. ulcerans during antibiotic chemotherapy ten months earlier which became clinically apparent due to a late inflammatory response to residual mycobacterial antigens (i.e., late paradoxical reaction), or to re-inoculation of M. ulcerans that was cleared by an elevated immune response primed by the successful initial treatment. However, available laboratory methods did not allow distinguishing between late paradoxical reaction and spontaneous host clearance during a second exposure.
While mycolactone plays a major role in the pathogenesis of primary BUD lesions, the question whether and to which extent the toxin is involved in the pathogenesis of secondary BUD lesions remains unresolved. Sarfo et al. recently demonstrated the detection of mycolactone in human tissue, suggesting its usefulness as a biomarker for monitoring the clinical response to treatment [8] . Detection of mycolactone in secondary lesions may support the hypothesis that new infection foci are associated with secondary lesions. However, to our knowledge, data on mycolactone in secondary lesions are still lacking.
Beside previous anecdotal observations on spontaneous clearance of lesions in clinically suspected BUD cases, Gordon et al. recently reported the first case of spontaneous resolution of a laboratory confirmed BUD ulcer in a patient from Australia [9] . Whereas the secondary lesions of the two BUD patients from Benin were surgically excised, the ulcerated lesion of the Togolese case also healed under conventional wound care.
In the absence of evidence-based guidelines for reliable identification of late-onset secondary immune-mediated lesions and their clinical management, it may be advisable to consider the possibility of spontaneous healing under stringent clinical observation and regular wound care.
